When should a time at risk start in efficacy malaria vaccine trials?

被引：0
|
作者：
Ejigu, Dawit Asmamaw [1 ]
机构：
[1] St Pauls Hosp, Millennium Med Coll, Pharmacol, Addis Ababa, Ethiopia
来源：
VACCINE | 2017年 / 35卷 / 02期
关键词：
D O I：
10.1016/j.vaccine.2016.11.019
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：201 / 201
页数：1
相关论文
共 50 条
  • [21] Evaluating the Efficacy of a Malaria Vaccine
    Small, Dylan S.
    Cheng, Jing
    Ten Have, Thomas R.
    INTERNATIONAL JOURNAL OF BIOSTATISTICS, 2010, 6 (02):
  • [22] Background risk should be taken into account when reporting vaccine effectiveness
    Zahradka, Ivan
    Petr, Vojtech
    Magicova, Maria
    Viklicky, Ondrej
    AMERICAN JOURNAL OF TRANSPLANTATION, 2022, 22 (07) : 1927 - 1928
  • [23] THE CHALLENGE OF MALARIA VACCINE - TRIALS AND TRIBULATIONS
    BRUCECHWATT, LJ
    LANCET, 1987, 1 (8529): : 371 - 373
  • [24] Molecular monitoring in malaria vaccine trials
    Felger, I
    Genton, B
    Smith, T
    Tanner, M
    Beck, HP
    TRENDS IN PARASITOLOGY, 2003, 19 (02) : 60 - 63
  • [25] HUMAN TRIALS BEGIN FOR MALARIA VACCINE
    WALSH, J
    SCIENCE, 1987, 235 (4794) : 1319 - 1320
  • [26] COLOMBIA MALARIA VACCINE APPROVED FOR TRIALS
    BROWN, P
    NEW SCIENTIST, 1992, 135 (1840) : 6 - 6
  • [27] MALARIA VACCINE VINDICATED IN COLOMBIAN TRIALS
    BROWN, P
    NEW SCIENTIST, 1993, 137 (1866) : 7 - 7
  • [28] Malaria vaccine trials in a wormy world
    Nacher, M
    TRENDS IN PARASITOLOGY, 2001, 17 (12) : 563 - 565
  • [29] New World monkey efficacy trials for malaria vaccine development: critical path or detour?
    Heppner, DG
    Cummings, JF
    Ockenhouse, C
    Kester, KE
    Lyon, JA
    Gordon, DM
    TRENDS IN PARASITOLOGY, 2001, 17 (09) : 419 - 425
  • [30] WHEN SHOULD REGULAR DIALYSIS THERAPY START
    不详
    BRITISH MEDICAL JOURNAL, 1976, 1 (6015): : 921 - 921
12345